D
Atossa Therapeutics, Inc.
ATOS
$0.5897
-$0.0304-4.90%
D
Sell
3/1/2024Upgraded
Atossa Therapeutics, Inc. (ATOS) was upgraded to D- from E+ on 3/1/2024 due to an increase in the volatility index and total return index.
Atossa Therapeutics, Inc. (ATOS) was upgraded to D- from E+ on 3/1/2024 due to an increase in the volatility index and total return index.
E
Sell
2/14/2024Downgrade
Atossa Therapeutics, Inc. (ATOS) was downgraded to E+ from D- on 2/14/2024 due to a decline in the volatility index and growth index.
Atossa Therapeutics, Inc. (ATOS) was downgraded to E+ from D- on 2/14/2024 due to a decline in the volatility index and growth index.
D
Sell
1/25/2024Upgraded
Atossa Therapeutics, Inc. (ATOS) was upgraded to D- from E+ on 1/25/2024 due to an increase in the volatility index.
Atossa Therapeutics, Inc. (ATOS) was upgraded to D- from E+ on 1/25/2024 due to an increase in the volatility index.
E
Sell
1/9/2024Downgrade
Atossa Therapeutics, Inc. (ATOS) was downgraded to E+ from D- on 1/9/2024 due to a decline in the volatility index.
Atossa Therapeutics, Inc. (ATOS) was downgraded to E+ from D- on 1/9/2024 due to a decline in the volatility index.
D
Sell
12/11/2023Upgraded
Atossa Therapeutics, Inc. (ATOS) was upgraded to D- from E+ on 12/11/2023 due to an increase in the volatility index and total return index.
Atossa Therapeutics, Inc. (ATOS) was upgraded to D- from E+ on 12/11/2023 due to an increase in the volatility index and total return index.
E
Sell
11/24/2023Downgrade
Atossa Therapeutics, Inc. (ATOS) was downgraded to E+ from D- on 11/24/2023 due to a decline in the volatility index, solvency index and total return index. The quick ratio declined from 28.79 to 27.31.
Atossa Therapeutics, Inc. (ATOS) was downgraded to E+ from D- on 11/24/2023 due to a decline in the volatility index, solvency index and total return index. The quick ratio declined from 28.79 to 27.31.
D
Sell
11/10/2023Upgraded
Atossa Therapeutics, Inc. (ATOS) was upgraded to D- from E+ on 11/10/2023 due to an increase in the volatility index and total return index.
Atossa Therapeutics, Inc. (ATOS) was upgraded to D- from E+ on 11/10/2023 due to an increase in the volatility index and total return index.
E
Sell
10/26/2023Downgrade
Atossa Therapeutics, Inc. (ATOS) was downgraded to E+ from D- on 10/26/2023 due to a decline in the growth index, volatility index and solvency index. Earnings per share declined from -$0.0496 to -$0.0776, the quick ratio declined from 35.53 to 28.79, and EBIT declined 9.79% from -$7.1M to -$7.79M.
Atossa Therapeutics, Inc. (ATOS) was downgraded to E+ from D- on 10/26/2023 due to a decline in the growth index, volatility index and solvency index. Earnings per share declined from -$0.0496 to -$0.0776, the quick ratio declined from 35.53 to 28.79, and EBIT declined 9.79% from -$7.1M to -$7.79M.
D
Sell
6/7/2023Upgraded
Atossa Therapeutics, Inc. (ATOS) was upgraded to D- from E+ on 6/7/2023 due to an increase in the total return index, volatility index and valuation index.
Atossa Therapeutics, Inc. (ATOS) was upgraded to D- from E+ on 6/7/2023 due to an increase in the total return index, volatility index and valuation index.
E
Sell
3/14/2023Downgrade
Atossa Therapeutics, Inc. (ATOS) was downgraded to E+ from D- on 03/14/2023.
Atossa Therapeutics, Inc. (ATOS) was downgraded to E+ from D- on 03/14/2023.
D
Sell
2/23/2023Upgraded
Atossa Therapeutics, Inc. (ATOS) was upgraded to D- from E+ on 02/23/2023.
Atossa Therapeutics, Inc. (ATOS) was upgraded to D- from E+ on 02/23/2023.
E
Sell
2/8/2023Downgrade
Atossa Therapeutics, Inc. (ATOS) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index and volatility index.
Atossa Therapeutics, Inc. (ATOS) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index and volatility index.
D
Sell
11/30/2022Downgrade
Atossa Therapeutics, Inc. (ATOS) was downgraded to D- from D on 11/30/2022 due to a decline in the total return index and volatility index.
Atossa Therapeutics, Inc. (ATOS) was downgraded to D- from D on 11/30/2022 due to a decline in the total return index and volatility index.
D
Sell
11/14/2022Upgraded
Atossa Therapeutics, Inc. (ATOS) was upgraded to D from D- on 11/14/2022 due to an increase in the growth index and valuation index. Operating cash flow increased 9.06% from -$5.95M to -$5.41M.
Atossa Therapeutics, Inc. (ATOS) was upgraded to D from D- on 11/14/2022 due to an increase in the growth index and valuation index. Operating cash flow increased 9.06% from -$5.95M to -$5.41M.
D
Sell
11/7/2022Downgrade
Atossa Therapeutics, Inc. (ATOS) was downgraded to D- from D on 11/7/2022 due to a decline in the growth index, volatility index and solvency index. The quick ratio declined from 56.91 to 33.34, earnings per share declined from -$0.0378 to -$0.0527, and EBIT declined 38.93% from -$4.75M to -$6.6M.
Atossa Therapeutics, Inc. (ATOS) was downgraded to D- from D on 11/7/2022 due to a decline in the growth index, volatility index and solvency index. The quick ratio declined from 56.91 to 33.34, earnings per share declined from -$0.0378 to -$0.0527, and EBIT declined 38.93% from -$4.75M to -$6.6M.
D
Sell
6/7/2022Upgraded
Atossa Therapeutics, Inc. (ATOS) was upgraded to D from D- on 6/7/2022 due to an increase in the volatility index.
Atossa Therapeutics, Inc. (ATOS) was upgraded to D from D- on 6/7/2022 due to an increase in the volatility index.
D
Sell
5/10/2022Downgrade
Atossa Therapeutics, Inc. (ATOS) was downgraded to D- from D on 5/10/2022 due to a decline in the growth index, total return index and solvency index. Operating cash flow declined 33.08% from -$3.67M to -$4.88M.
Atossa Therapeutics, Inc. (ATOS) was downgraded to D- from D on 5/10/2022 due to a decline in the growth index, total return index and solvency index. Operating cash flow declined 33.08% from -$3.67M to -$4.88M.
D
Sell
4/21/2022Upgraded
Atossa Therapeutics, Inc. (ATOS) was upgraded to D from E+ on 04/21/2022.
Atossa Therapeutics, Inc. (ATOS) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
Atossa Therapeutics, Inc. (ATOS) was downgraded to E+ from D on 4/20/2022 due to a significant decline in the total return index, growth index and volatility index. Operating cash flow declined 19.73% from -$3.06M to -$3.67M.
Atossa Therapeutics, Inc. (ATOS) was downgraded to E+ from D on 4/20/2022 due to a significant decline in the total return index, growth index and volatility index. Operating cash flow declined 19.73% from -$3.06M to -$3.67M.
D
Sell
12/9/2021Downgrade
Atossa Therapeutics, Inc. (ATOS) was downgraded to D from D+ on 12/9/2021 due to a decline in the volatility index and total return index.
Atossa Therapeutics, Inc. (ATOS) was downgraded to D from D+ on 12/9/2021 due to a decline in the volatility index and total return index.
D
Sell
11/16/2021Upgraded
Atossa Therapeutics, Inc. (ATOS) was upgraded to D+ from D- on 11/16/2021 due to a noticeable increase in the growth index, volatility index and total return index. Operating cash flow increased 42.63% from -$5.34M to -$3.06M, earnings per share increased from -$0.0579 to -$0.0411, and EBIT increased 26.35% from -$7M to -$5.16M.
Atossa Therapeutics, Inc. (ATOS) was upgraded to D+ from D- on 11/16/2021 due to a noticeable increase in the growth index, volatility index and total return index. Operating cash flow increased 42.63% from -$5.34M to -$3.06M, earnings per share increased from -$0.0579 to -$0.0411, and EBIT increased 26.35% from -$7M to -$5.16M.
D
Sell
11/8/2021Downgrade
Atossa Therapeutics, Inc. (ATOS) was downgraded to D- from D on 11/8/2021 due to a decline in the growth index and valuation index. EBIT declined 98.37% from -$3.53M to -$7M, earnings per share declined from -$0.0382 to -$0.0579, and operating cash flow declined 21.04% from -$4.41M to -$5.34M.
Atossa Therapeutics, Inc. (ATOS) was downgraded to D- from D on 11/8/2021 due to a decline in the growth index and valuation index. EBIT declined 98.37% from -$3.53M to -$7M, earnings per share declined from -$0.0382 to -$0.0579, and operating cash flow declined 21.04% from -$4.41M to -$5.34M.
D
Sell
5/1/2020Upgraded
Atossa Therapeutics, Inc. (ATOS) was upgraded to D from D- on 5/1/2020 due to an increase in the growth index and volatility index. EBIT increased 20.66% from -$3.3M to -$2.62M, and earnings per share increased from -$0.3599 to -$0.2865.
Atossa Therapeutics, Inc. (ATOS) was upgraded to D from D- on 5/1/2020 due to an increase in the growth index and volatility index. EBIT increased 20.66% from -$3.3M to -$2.62M, and earnings per share increased from -$0.3599 to -$0.2865.
D
Sell
6/7/2019Downgrade
Atossa Genetics Inc. (ATOS) was downgraded to D- from D on 6/7/2019 due to a decline in the volatility index and total return index.
Atossa Genetics Inc. (ATOS) was downgraded to D- from D on 6/7/2019 due to a decline in the volatility index and total return index.
D
Sell
5/15/2019Upgraded
Atossa Genetics Inc. (ATOS) was upgraded to D from D- on 5/15/2019 due to an increase in the total return index, volatility index and solvency index. The quick ratio increased from 3.74 to 13.28.
Atossa Genetics Inc. (ATOS) was upgraded to D from D- on 5/15/2019 due to an increase in the total return index, volatility index and solvency index. The quick ratio increased from 3.74 to 13.28.
D
Sell
8/15/2018Upgraded
Atossa Genetics Inc. (ATOS) was upgraded to D- from E+ on 8/15/2018 due to an increase in the efficiency index and solvency index. Total capital increased 157.94% from $5.26M to $13.57M.
Atossa Genetics Inc. (ATOS) was upgraded to D- from E+ on 8/15/2018 due to an increase in the efficiency index and solvency index. Total capital increased 157.94% from $5.26M to $13.57M.
E
Sell
5/15/2018Downgrade
Atossa Genetics Inc. (ATOS) was downgraded to E+ from D- on 5/15/2018 due to a decline in the growth index, efficiency index and solvency index. Operating cash flow declined 41.85% from -$1.68M to -$2.39M, total capital declined 24.2% from $6.94M to $5.26M, and EBIT declined 21.05% from -$1.55M to -$1.87M.
Atossa Genetics Inc. (ATOS) was downgraded to E+ from D- on 5/15/2018 due to a decline in the growth index, efficiency index and solvency index. Operating cash flow declined 41.85% from -$1.68M to -$2.39M, total capital declined 24.2% from $6.94M to $5.26M, and EBIT declined 21.05% from -$1.55M to -$1.87M.
D
Sell
5/7/2018Upgraded
Atossa Genetics Inc. (ATOS) was upgraded to D- from E+ on 5/7/2018 due to an increase in the valuation index and total return index.
Atossa Genetics Inc. (ATOS) was upgraded to D- from E+ on 5/7/2018 due to an increase in the valuation index and total return index.
E
Sell
4/19/2018Downgrade
Atossa Genetics Inc. (ATOS) was downgraded to E+ from D- on 4/19/2018 due to a decline in the valuation index.
Atossa Genetics Inc. (ATOS) was downgraded to E+ from D- on 4/19/2018 due to a decline in the valuation index.
D
Sell
1/31/2018Upgraded
Atossa Genetics Inc. (ATOS) was upgraded to D- from E+ on 1/31/2018 due to an increase in the volatility index.
Atossa Genetics Inc. (ATOS) was upgraded to D- from E+ on 1/31/2018 due to an increase in the volatility index.
E
Sell
11/8/2017Downgrade
Atossa Genetics Inc. (ATOS) was downgraded to E+ from D- on 11/8/2017 due to a decline in the volatility index.
Atossa Genetics Inc. (ATOS) was downgraded to E+ from D- on 11/8/2017 due to a decline in the volatility index.
D
Sell
10/24/2017Upgraded
Atossa Genetics Inc. (ATOS) was upgraded to D- from E+ on 10/24/2017 due to an increase in the growth index, solvency index and volatility index. The quick ratio increased from 1.51 to 1.94, and operating cash flow increased 27.53% from -$1.86M to -$1.35M.
Atossa Genetics Inc. (ATOS) was upgraded to D- from E+ on 10/24/2017 due to an increase in the growth index, solvency index and volatility index. The quick ratio increased from 1.51 to 1.94, and operating cash flow increased 27.53% from -$1.86M to -$1.35M.
E
Sell
3/21/2017Downgrade
Atossa Genetics Inc. (ATOS) was downgraded to E+ from D- on 3/21/2017 due to a decline in the growth index, efficiency index and valuation index. Earnings per share declined from $0.0731 to -$1.0566, net income declined 1,332.88% from $204.7 to -$2.52M, and operating cash flow declined 313.38% from $635.5 to -$1.36M.
Atossa Genetics Inc. (ATOS) was downgraded to E+ from D- on 3/21/2017 due to a decline in the growth index, efficiency index and valuation index. Earnings per share declined from $0.0731 to -$1.0566, net income declined 1,332.88% from $204.7 to -$2.52M, and operating cash flow declined 313.38% from $635.5 to -$1.36M.
D
Sell
2/27/2017Upgraded
Atossa Genetics Inc. (ATOS) was upgraded to D- from E+ on 2/27/2017 due to a major increase in the growth index, efficiency index and solvency index. The quick ratio increased from 1.36 to 5.08, operating cash flow increased 138.3% from -$1.66M to $635.5, and total capital increased 124.63% from $2.41M to $5.41M.
Atossa Genetics Inc. (ATOS) was upgraded to D- from E+ on 2/27/2017 due to a major increase in the growth index, efficiency index and solvency index. The quick ratio increased from 1.36 to 5.08, operating cash flow increased 138.3% from -$1.66M to $635.5, and total capital increased 124.63% from $2.41M to $5.41M.
E
Sell
4/1/2016Downgrade
Atossa Genetics, Inc. (ATOS) was downgraded to E+ from D- on 4/1/2016 due to a noticeable decline in the growth index, solvency index and efficiency index. Total capital declined 58.7% from $9.06M to $3.74M, and the quick ratio declined from 2.7 to 1.49.
Atossa Genetics, Inc. (ATOS) was downgraded to E+ from D- on 4/1/2016 due to a noticeable decline in the growth index, solvency index and efficiency index. Total capital declined 58.7% from $9.06M to $3.74M, and the quick ratio declined from 2.7 to 1.49.
D
Sell
3/11/2016Downgrade
Atossa Genetics, Inc. (ATOS) was downgraded to D- from D on 3/11/2016 due to a major decline in the volatility index, solvency index and total return index. The quick ratio declined from 3.93 to 2.7.
Atossa Genetics, Inc. (ATOS) was downgraded to D- from D on 3/11/2016 due to a major decline in the volatility index, solvency index and total return index. The quick ratio declined from 3.93 to 2.7.
NASDAQ
04/10/2025 4:00PM Eastern
Quotes delayed
